NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT05434689 2026-04-15
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT03500445 2026-04-13
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03798678 2026-04-13
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05050097 2026-04-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05675449 2026-04-13
MagnetisMM-20
Pfizer
Phase 1 Active not recruiting
NCT04933539 2026-04-01
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting